New drug targets rare gene mutations in Hard-to-Treat cancers
NCT ID NCT06351371
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a pill called erdafitinib in 35 adults whose cancers have specific FGFR gene mutations or fusions. The drug blocks a faulty protein that helps cancer grow, potentially shrinking tumors or slowing the disease. It is a phase 2 trial for advanced solid tumors that have not responded to other treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT SOLID NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
ECOG-ACRIN Cancer Research Group
Philadelphia, Pennsylvania, 19103, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new PET tracer reveal hidden immune clues in tumors?
- A hug in a blanket: could deep pressure calm cancer infusion anxiety?
- A virtual pharmacy visit may ease opioid fears for cancer patients
- Can meditation tame the Long-Term side effects of a stem cell transplant?
- Strumming through treatment: can ukulele lessons shield teen brains from Radiation's toll?
- A smartphone app may help young cancer survivors get fitter — a trial puts it to the test